Agile Therapeutics (AGRX) PT Lowered to $8 at Oppenheimer

Oppenheimer analyst Leland Gershell lowered the price target on Agile Therapeutics (NASDAQ: AGRX) to $8.00 (from $9.00) while maintaining an Outperform rating.

The analyst commented, "With approved once-weekly contraceptive patch Twirla positioned to launch in 4Q20 and ample cash resources following recent financings, we highlight AGRX as offering an attractive fundamental picture for small-cap biopharma investors. With shares -37% YTD and -54% since Twirla's mid-February approval, we reiterate our Outperform and recommend investors take advantage of current levels to build positions."

You May Also Be Interested In

• QuantumScape (QS) PT Lowered to $6 at Truist Securities
• Westamerica Bancorp (WABC) PT Lowered to $50 at Piper Sandler
• Piper Sandler Downgrades Magnolia Oil & Gas Corp. (MGY) to Neutral